Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction

References

• Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients–recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011;46:709-18
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12
   PubMed Web of Science ®Google Scholar
• Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010;88:115-19
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-31
   PubMed Web of Science ®Google Scholar
• Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71
   PubMed Web of Science ®Google Scholar
• Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51
   PubMed Web of Science ®Google Scholar
• Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5
   PubMed Web of Science ®Google Scholar
• Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545-52
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007;23:1415-22
   PubMed Web of Science ®Google Scholar
• Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008;118:69-86
   PubMed Web of Science ®Google Scholar
• Clark BG, Jue SG, Dawson GW, et al. Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. Drugs 1986;31:500-16
   PubMed Web of Science ®Google Scholar
• Heel RC, Brogden RN, Speight TM, et al. Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs 1981;21:321-40
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Raggi MA. Benzodiazepine metabolism: an analytical perspective. Curr Drug Metab 2008;9:827-44
   PubMed Web of Science ®Google Scholar
• Court MH, Duan SX, Guillemette C, et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 2002;30:1257-65
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Divoll M, Abernethy DR, et al. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1983;8:233-52
   PubMed Web of Science ®Google Scholar
• Kahle K, Langmann P, Schirmer D, et al. Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother 2009;53:3140-2
   PubMed Web of Science ®Google Scholar
• Krishna G, AbuTarif M, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008;28:1223-32
   PubMed Web of Science ®Google Scholar
• Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36
   PubMed Web of Science ®Google Scholar
• Heinz WJ, Zirkel J, Kuhn A, et al. Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother 2011;55:3621-3
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51:3617-26
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009;51:437-44
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Gustafsson LL, Sawe J, et al. Metabolic interaction between morphine and various benzodiazepines. Acta Pharmacol Toxicol (Copenh) 1986;58:249-52
   PubMedGoogle Scholar
• Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-22
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710
   PubMed Web of Science ®Google Scholar
• Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;79:362-70
   PubMed Web of Science ®Google Scholar
• Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-16
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91
   PubMed Web of Science ®Google Scholar
• Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit 1996;18:124-7
   PubMed Web of Science ®Google Scholar
• Sawamura R, Sato H, Kawakami J, et al. Inhibitory effect of azole antifungal agents on the glucuronidation of lorazepam using rabbit liver microsomes in vitro. Biol Pharm Bull 2000;23:669-71
   PubMed Web of Science ®Google Scholar
• Li Y, Theuretzbacher U, Clancy CJ, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010;49:379-96
   PubMed Web of Science ®Google Scholar
• Katragkou A, Tsikopoulou F, Roilides E, et al. Posaconazole: when and how? The clinician's view. Mycoses 2011 Jul 18. doi: 10.1111/j.1439-0507.2011.02061.x. [Epub ahead of print]
   Google Scholar
• Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 2003;65:1441-9
   PubMed Web of Science ®Google Scholar
• Ochs HR, Otten H, Greenblatt DJ, et al. Diazepam absorption: effects of age, sex, and Billroth gastrectomy. Dig Dis Sci 1982;27:225-30
   PubMed Web of Science ®Google Scholar